A deep dive into Lupin Ltd. (LUPIN) — examining the financials, valuation picture, and who owns the stock.
Lupin Revenue Trend
A 13.8% jump in revenue took Lupin Ltd.'s top line to ₹22,904 Cr in FY2025.
The 10-year revenue CAGR of 6.0% reflects steady — if not spectacular — top-line expansion from ₹12,770 Cr to ₹22,904 Cr.
With a top line of ₹22,904 Cr, Lupin Ltd. operates at a major scale within the pharmaceuticals sector.
Looking at the year-on-year numbers, Lupin Ltd. has seen 4 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹22,904 Cr | +13.8% |
| FY2024 | ₹20,131 Cr | +20.4% |
| FY2023 | ₹16,715 Cr | +1.0% |
| FY2022 | ₹16,547 Cr | +9.1% |
| FY2021 | ₹15,163 Cr | — |
View Lupin Ltd.'s full 10-year revenue trend with CAGR analysis →
Lupin Profitability
A 70.8% improvement in net profit took Lupin Ltd.'s bottom line to ₹3,306 Cr in FY2025.
On the margin front, there's improvement — net margin went from 9.6% in FY2024 to 14.4% in FY2025.
Earnings per share (diluted) were ₹71.69 in FY2025, up from ₹41.87.
Is Lupin Undervalued
Lupin Ltd. shares are currently trading at ₹2,396.30.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Lupin Shareholding Pattern
At 46.9%, the promoter stake has been flat for the past 4 quarters.
Foreign institutions moved their stake up to 21.7% from 21.2% over the past year.
DII holding is at 25.3%, down from 25.6% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 46.9% | 21.7% | 25.3% | 6.1% |
| Dec 2025 | 46.9% | 21.5% | 25.6% | 6.0% |
| Sep 2025 | 46.9% | 20.5% | 26.6% | 6.1% |
| Jun 2025 | 46.9% | 21.2% | 25.6% | 6.3% |
Track quarterly shareholding changes for Lupin Ltd. →
Lupin Balance Sheet
Proportional view as of 23 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹292.05B (up 21.7% YoY from ₹239.97B).
Top categories: Other Assets (19.7%), Receivables (18.8%), Inventories (18.8%).
Of the ₹292.05B in liabilities and equity, 59.2% is shareholder equity, 18.7% is interest-bearing debt, and 22.1% is operating liabilities. Over the year, debt is up 86.5% and equity is up 20.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 26.03B |
| Receivables | 54.97B |
| Inventories | 54.76B |
| Property, Plant & Equipment | 50.55B |
| Investments | 872.70M |
| Intangibles & Goodwill | 47.32B |
| Other Assets | 57.54B |
| Category | Value |
|---|---|
| Equity | 172.94B |
| Short-term Debt | 34.17B |
| Long-term Debt | 20.31B |
| Trade Payables | 29.58B |
| Other Liabilities | 35.05B |
Lupin Investment Snapshot
To sum up Lupin Ltd.'s financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹22,904 Cr in FY2025, up 13.8% year-over-year.
Long-term revenue has been compounding at 6.0% annually over 10 years.
The company is profitable, with a net margin of 14.4% and net income of ₹3,306 Cr.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Lupin Ltd. includes three valuation models, decade-long financials, and insider activity.